FHIT、Ki67和bax在宫颈癌中的表达及临床意义
Expression of FHIT, Ki67 and bax and Clinical Significance in Cervix Carcinoma
-
摘要: 目的 观察FHIT、Ki6 7和bax在宫颈癌组织中的表达情况, 探讨FHIT、Ki6 7和bax与宫颈癌临床病理指标及预后之间的关系。方法 应用免疫组化方法检测 5 0例宫颈癌和 2 0例正常宫颈组织中FHIT、Ki6 7和bax蛋白的表达。结果 5 0例宫颈癌中, 2 6例 (5 2 % )显示FHIT蛋白表达降低或缺失, 36例 (72 % )Ki6 7表达阳性, 31例 (6 2 % )bax表达阳性。FHIT表达的降低或缺失不仅与肿瘤的高分级(P =0 .0 0 3)和淋巴结转移 (P =0 .0 0 2 )明显相关, 而且与宫颈癌的复发和死亡关系密切 (P =0 .0 19)。bax蛋白的表达随病理分级的升高而降低 (P =0 .0 12 )。FHIT蛋白的表达与bax的表达成正相关 (rs=0 .340, P =0 .0 16 ), 与Ki6 7的表达成负相关 (rs=- 0 .2 92, P =0 .0 39)。结论 FHIT的异常表达在宫颈癌的发展中起着重要作用, 而且可为宫颈癌的评估提供重要的预后信息Abstract: Objective To investigate the expression of FHIT, Ki67 and bax and their relationship with clinicopathologic parameters and prognosis in cervix carcinoma. Methods Immunohistochemical analysis was performed in 50 invasive cervix carcinomas and 20 normal cervix tissues. Results Reduction or absence of FHIT expression was found in 52%(26/50)of the tumors. Positive staining of Ki67 was detected in 36 of 50 (72%) cervix carcinomas. Bax immunoreactivity was observed in 31 of 50 (62%) cervix carcinomas. Loss of FH...
下载:
